| 2.66 -0.02 (-0.75%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.74 | 1-year : | 4.85 |
| Resists | First : | 3.2 | Second : | 4.15 |
| Pivot price | 2.93 |
|||
| Supports | First : | 1.66 | Second : | 1.38 |
| MAs | MA(5) : | 2.64 |
MA(20) : | 3.11 |
| MA(100) : | 2.01  |
MA(250) : | 1.73 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 12.3 |
D(3) : | 10 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 4.15 | Low : | 0.94 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NUVB ] has closed above bottom band by 25.8%. Bollinger Bands are 60.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 40 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.78 - 2.79 | 2.79 - 2.81 |
| Low: | 2.62 - 2.63 | 2.63 - 2.65 |
| Close: | 2.63 - 2.66 | 2.66 - 2.69 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Wed, 24 Apr 2024
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical ... - Business Wire
Fri, 19 Apr 2024
Nuvation Bio (NYSE:NUVB) Trading Up 5% - MarketBeat
Sun, 31 Mar 2024
Nuvation Bio: Strong Buy Off Acquisition Of A Late-Stage Lung Cancer Candidate (NYSE:NUVB) - Seeking Alpha
Thu, 28 Mar 2024
Premarket Mover: Nuvation Bio Inc (NUVB) Up 1.01% - InvestorsObserver
Tue, 26 Mar 2024
Nuvation Bio shares upgraded on promising drug prospects By Investing.com - Investing.com
Mon, 25 Mar 2024
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 246 (M) |
| Shares Float | 136 (M) |
| Held by Insiders | 24.5 (%) |
| Held by Institutions | 55 (%) |
| Shares Short | 3,010 (K) |
| Shares Short P.Month | 2,650 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -9.7 % |
| Return on Equity (ttm) | -12.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -68 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -7.61 |
| PEG Ratio | 0 |
| Price to Book value | 0.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|